NCT02079870View on ClinicalTrials.gov

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 6, 2014

Primary Completion Date

January 7, 2015

Study Completion Date

January 7, 2015

Conditions
DiabetesMetabolism and Nutrition DisorderObesity
Interventions
DRUG

semaglutide

Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks

DRUG

placebo

Solution for subcutaneous (s.c. - under the skin) injection

Trial Locations (1)

LS2 9LH

Novo Nordisk Investigational Site, Leeds

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY